Analysts Set Theravance Biopharma, Inc. (NASDAQ:TBPH) Target Price at $13.75

Shares of Theravance Biopharma, Inc. (NASDAQ:TBPH) have received an average rating of “Hold” from the five research firms that are covering the firm, Marketbeat reports. Three research analysts have rated the stock with a hold recommendation and two have assigned a buy recommendation to the company. The average 12 month price target among brokerages that have updated their coverage on the stock in the last year is $13.75.

Several research firms have issued reports on TBPH. Leerink Partnrs cut shares of Theravance Biopharma from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, August 6th. HC Wainwright decreased their price target on shares of Theravance Biopharma from $20.00 to $15.00 and set a “buy” rating on the stock in a research note on Tuesday, August 6th. Leerink Partners cut shares of Theravance Biopharma from an “outperform” rating to a “market perform” rating and decreased their price target for the stock from $15.00 to $10.00 in a research note on Tuesday, August 6th. TD Cowen decreased their price target on shares of Theravance Biopharma from $10.00 to $9.00 and set a “hold” rating on the stock in a research note on Tuesday, August 6th. Finally, StockNews.com cut shares of Theravance Biopharma from a “buy” rating to a “hold” rating in a research note on Saturday, August 10th.

Insider Buying and Selling

In related news, major shareholder Eli Samaha bought 999,800 shares of the firm’s stock in a transaction that occurred on Wednesday, August 7th. The shares were acquired at an average cost of $7.80 per share, with a total value of $7,798,440.00. Following the completion of the transaction, the insider now owns 9,511,150 shares of the company’s stock, valued at $74,186,970. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. In related news, SVP Rhonda Farnum sold 4,000 shares of the firm’s stock in a transaction that occurred on Wednesday, July 10th. The shares were sold at an average price of $9.00, for a total value of $36,000.00. Following the sale, the senior vice president now directly owns 335,965 shares of the company’s stock, valued at $3,023,685. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, major shareholder Eli Samaha purchased 999,800 shares of the business’s stock in a transaction that occurred on Wednesday, August 7th. The stock was acquired at an average price of $7.80 per share, for a total transaction of $7,798,440.00. Following the acquisition, the insider now directly owns 9,511,150 shares of the company’s stock, valued at approximately $74,186,970. The disclosure for this purchase can be found here. Corporate insiders own 6.90% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of the business. Oasis Management Co Ltd. raised its holdings in Theravance Biopharma by 5.6% in the fourth quarter. Oasis Management Co Ltd. now owns 1,006,858 shares of the biopharmaceutical company’s stock valued at $11,317,000 after buying an additional 53,604 shares during the period. Jacobs Levy Equity Management Inc. raised its holdings in Theravance Biopharma by 41.6% in the first quarter. Jacobs Levy Equity Management Inc. now owns 557,971 shares of the biopharmaceutical company’s stock valued at $5,005,000 after buying an additional 163,951 shares during the period. Dimensional Fund Advisors LP raised its holdings in Theravance Biopharma by 38.4% in the second quarter. Dimensional Fund Advisors LP now owns 330,181 shares of the biopharmaceutical company’s stock valued at $2,800,000 after buying an additional 91,679 shares during the period. Marshall Wace LLP raised its holdings in Theravance Biopharma by 83.6% in the second quarter. Marshall Wace LLP now owns 297,499 shares of the biopharmaceutical company’s stock valued at $2,523,000 after buying an additional 135,426 shares during the period. Finally, Wellington Management Group LLP raised its holdings in Theravance Biopharma by 68.0% in the fourth quarter. Wellington Management Group LLP now owns 287,102 shares of the biopharmaceutical company’s stock valued at $3,227,000 after buying an additional 116,164 shares during the period. Hedge funds and other institutional investors own 99.10% of the company’s stock.

Theravance Biopharma Price Performance

Shares of NASDAQ TBPH opened at $8.01 on Friday. Theravance Biopharma has a 52 week low of $7.44 and a 52 week high of $11.71. The company’s 50-day moving average price is $8.83 and its 200 day moving average price is $8.93.

Theravance Biopharma (NASDAQ:TBPH) last issued its quarterly earnings data on Monday, August 5th. The biopharmaceutical company reported ($0.34) EPS for the quarter, missing analysts’ consensus estimates of ($0.09) by ($0.25). The business had revenue of $14.26 million during the quarter, compared to analyst estimates of $15.81 million. Theravance Biopharma had a negative net margin of 73.61% and a negative return on equity of 21.29%. During the same period in the previous year, the company posted ($0.28) earnings per share. Equities research analysts forecast that Theravance Biopharma will post -1.04 earnings per share for the current fiscal year.

Theravance Biopharma Company Profile

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.